A strong theme ran through Day 2:
Stakeholders have stopped debating whether real world evidence belongs at the decision table. The conversation has moved to how to generate RWE that is credible, transparent, and ready to inform real decisions.
Across sessions on rare oncology, IRA negotiations, value assessment, and publication standards, several priorities kept resurfacing:
🔹 methodological rigour and pre specification
🔹 transparency and reproducibility
🔹 earlier evidence planning across the product lifecycle
🔹 decision grade data rather than more data
🔹 closer partnership between industry, HTA bodies, and academia
One particularly relevant discussion focused on closing evidence gaps for medical devices and diagnostics through registries, research collaborations, and regulatory data.
Great to see Mattias Kyhlstedt from athagoras MedTech contributing to the panel: “Closing the Clinical Impact Evidence Gap: Practical RWE Strategies for Medical Devices and Diagnostics Using Registries, Research Partners and Regulatory Data.”
Another takeaway from Day 2: More evidence does not automatically lead to better decisions. Trust in how that evidence is generated may become the defining challenge for the next phase of HEOR and RWE.
Tomorrow marks the final day of ISPOR 2026. As part of the athagoras Group, we look forward to continuing conversations with colleagues and partners while observing which themes will define the final discussions of this year’s meeting.
What do you think will matter most for the future of RWE: transparency, interoperability, or implementation?
